Study of chronic myeloid leukemia patients in treatment-free remission
Part of Blood & lymphatic, Cancer clinical trials.
This follow-up study looks at people with chronic myeloid leukemia (CML) who have been in deep remission and may be able to stay off treatment. It checks how long remission lasts and how their leukemia tests behave over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 20 or older) with chronic-phase CML
- Your leukemia genetic test shows BCR-ABL type e13a2 or e14a2 (p210)
- You have NOT previously shown resistance to nilotinib or dasatinib (second-generation tablets)
- You have taken imatinib for at least 5 straight years, or nilotinib/dasatinib for at least 4 straight years
- Your blood or bone marrow test has stayed very low (MR4.5 or undetectable) for at least 2 years, confirmed on at least 4 separate tests
- You can get a sensitive qPCR BCR-ABL test that can detect down to MR4.5
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether some people with chronic myeloid leukemia (CML) can stop CML pills and still keep the disease under control. It is for people who are newly diagnosed or whose current CML treatment did not work well or caused side effects.
This study keeps records of people with chronic-phase CML who stopped their targeted leukemia pills (TKIs) while in a very deep remission. Researchers want to understand outcomes after stopping treatment and how often remissions are maintained.
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
This Phase 2 trial tests a combination treatment to try to get rid of remaining cancer cells in young adults whose acute myeloid leukemia (AML) is in remission but still detectable at low levels. It may help patients eliminate “minimal residual disease” (small traces of leukemia cells) and reduce relapse risk.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
Hear when a new Chronic Myeloid Leukemia, BCR/ABL-Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.